BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2021 11:15:33 AM | Browse: 472 | Download: 750
 |
Received |
|
2021-03-19 22:09 |
|
Peer-Review Started |
|
2021-03-19 22:11 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-01 03:35 |
|
Revised |
|
2021-05-13 06:34 |
|
Second Decision |
|
2021-11-15 03:34 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-11-15 07:02 |
|
Articles in Press |
|
2021-11-15 07:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-16 15:20 |
|
Publish the Manuscript Online |
|
2021-11-19 11:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Frontier |
| Article Title |
Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
John Gubatan, Derek R Holman, Christopher J Puntasecca, Danielle Polevoi, Samuel JS Rubin and Stephan Rogalla |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Chan Zuckerberg Biohub Physician Scientist Scholar Award |
|
| National Institutes of Health NIDDK Clinical Research Loan Repayment Program Award |
|
|
| Corresponding Author |
John Gubatan, MD, Consultant Physician-Scientist, Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 420 Broadway Street Pavilion D, 2nd Floor
, Redwood City, CA 94063, United States. jgubatan@stanford.edu |
| Key Words |
Antimicrobial peptides; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Gut microbiome; Biomarkers |
| Core Tip |
Antimicrobial peptides (AMPs) play critical roles in protecting against infection while maintaining intestinal homeostasis to support commensalism with the gut microbiome. AMPs have broad spectrum antimicrobial activity with diverse mechanisms of action and regulate gut microbiome composition. Defects in endogenous AMP expression and function have been linked with animal models of inflammatory bowel disease (IBD). Exogenous delivery of AMPs such as defensins, cathelicidin, and elafin attenuates intestinal inflammation in murine models of IBD. AMPs such as calprotectin and lactoferrin are useful biomarkers for patients with IBD. Challenges with AMP stability, bioavailability, and selectivity are major barriers to their application as potential therapies. |
| Publish Date |
2021-11-19 11:15 |
| Citation |
Gubatan J, Holman DR, Puntasecca CJ, Polevoi D, Rubin SJ, Rogalla S. Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. World J Gastroenterol 2021; 27(43): 7402-7422 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i43/7402.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i43.7402 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
